Trial Profile
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Ascorbic acid; Bortezomib; Carfilzomib; Cyclophosphamide; Dexamethasone; Doxorubicin; Lenalidomide; Melphalan; Pomalidomide; Prednisolone; Prednisone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biomira USA; Oncotherapeutics.
- 30 Oct 2023 Status changed from active, no longer recruiting to completed.
- 01 Jul 2022 Results published in the Experimental Hematology
- 13 Aug 2020 Planned End Date changed from 1 Jun 2020 to 1 Sep 2020.